Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

ClinicalTrials.gov ID: NCT00197145

Public ClinicalTrials.gov record NCT00197145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.

Study identification

NCT ID
NCT00197145
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
ViiV Healthcare
Industry
Enrollment
24 participants

Conditions and interventions

Interventions

  • GW873140 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 20, 2005
Primary completion
Sep 10, 2007
Completion
Sep 10, 2007
Last update posted
Nov 1, 2018

2005 – 2007

United States locations

U.S. sites
52
U.S. states
24
U.S. cities
46
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35294
GSK Investigational Site Beverly Hills California 90210
GSK Investigational Site Fountain Valley California 92708
GSK Investigational Site Laguna Beach California 92651
GSK Investigational Site Long Beach California 90813
GSK Investigational Site Los Angeles California 90046
GSK Investigational Site Los Angeles California 90069
GSK Investigational Site Oakland California 94609
GSK Investigational Site San Francisco California 94114
GSK Investigational Site Tarzana California 91356
GSK Investigational Site Glastonbury Connecticut 06033
GSK Investigational Site Norwalk Connecticut 06851
GSK Investigational Site Washington D.C. District of Columbia 20009
GSK Investigational Site Washington D.C. District of Columbia 20037
GSK Investigational Site Fort Lauderdale Florida 33306
GSK Investigational Site Fort Lauderdale Florida 33308
GSK Investigational Site Fort Myers Florida 33901
GSK Investigational Site Key West Florida 33040
GSK Investigational Site Miami Florida 33136
GSK Investigational Site Oakland Park Florida 33334
GSK Investigational Site Orlando Florida 32804
GSK Investigational Site Plantation Florida 33317
GSK Investigational Site Atlanta Georgia 30308/30309
GSK Investigational Site Atlanta Georgia 30339
GSK Investigational Site Decatur Georgia 30033
GSK Investigational Site Chicago Illinois 60613
GSK Investigational Site Chicago Illinois 60657
GSK Investigational Site Wichita Kansas 67214
GSK Investigational Site New Orleans Louisiana 70127-0800
GSK Investigational Site Portland Maine 04102
GSK Investigational Site Baltimore Maryland 21201
GSK Investigational Site Boston Massachusetts 02215
GSK Investigational Site Minneapolis Minnesota 55404
GSK Investigational Site St Louis Missouri 63108
GSK Investigational Site Las Vegas Nevada 89102
GSK Investigational Site East Orange New Jersey 07018
GSK Investigational Site Hillsborough New Jersey 08844
GSK Investigational Site Newark New Jersey 07102
GSK Investigational Site Mount Vernon New York 10550
GSK Investigational Site New York New York 10014
GSK Investigational Site Charlotte North Carolina 28209
GSK Investigational Site Akron Ohio 44304
GSK Investigational Site Portland Oregon 97209
GSK Investigational Site Portland Oregon 97219
GSK Investigational Site Columbia South Carolina 29206-4713
GSK Investigational Site Austin Texas 78746
GSK Investigational Site Dallas Texas 75246
GSK Investigational Site Houston Texas 77027
GSK Investigational Site Annandale Virginia 22003
GSK Investigational Site Hampton Virginia 23666
GSK Investigational Site Lynchburg Virginia 24501
GSK Investigational Site Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00197145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 1, 2018 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00197145 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →